Table 3 Survival analyses according to clinical and biochemical variables

Age

0.29

0.47

  < 63.1

8.7

6.2–11.2

17.5

5.5–29.4

  ≥ 63.1

20.4

3.2–37.7

15.0

12.4–17.6

Sex

0.03

0.87

 Female

NR

-

12.7

7.3–18.2

 Male

8.7

6.6–10.7

18.0

10.5–25.4

Number of disease sites

0.80

0.52

  ≤ 2

12.9

2.1–23.7

17.5

11.3–23.7

  > 2

9.1

8.3–9.8

13.9

10.2–17.6

Prior nephrectomy

0.07

<0.01

 Yes

14.7

5.9–23.5

26.0

20.1–31.8

 No

8.7

3.1–14.3

10.8

4.5–17.0

Pretreatment hypertension

0.42

0.79

 Yes

17.0

6.2–27.7

18.0

9.4–26.5

 No

8.4

3.7–13.1

11.6

5.3–17.9

Treatment induced early hypertension⁵ at week 6

0.68

0.85

 Yes

14.7

9.6–19.8

18.0

3.5–32.5

 No

8.7

3.9–13.5

12.1

3.8–20.4

Treatment induced early hypertension⁵ at week 12

<0.01

<0.01

 Yes

14.7

10.1–19.3

26.0

24.1–27.9

 No

2.6

1.9–3.3

7.7

4.4–11.0

IMDC risk score

0.10

<0.01

 Good

20.4

13.1–27.7

67.9

38.4–97.5

 Intermediate

9.1

6.0–12.2

12.7

10.6–14.9

 Poor

8.4

0–17.7

13.7

5.4–22.1

NLR baseline ≤3

0.05

0.06

 Yes

14.7

8.8–20.6

25.2

10.6–39.8

 No

6.7

2.0–11.4

13.2

10.3–16.1

NLR week 6 ≤ 3

0.09

<0.01

 Yes

10.8

6.0–15.7

25.2

13.7–36.7

 No

1.8

0.2–3.5

3.8

3.3–4.3

NLR shifted from >3 to ≤3 week 6

<0.01

<0.01

 Yes

8.4

6.0–10.7

13.2

7.0–19.4

 No

1.3

0.9–1.7

3.6

0.8–6.4

NLR shifted from ≤3 to >3 at week 6

0.75

0.16

 Yes

NR

-

4.0

2.3–5.7

 No

14.7

9.2–20.3

26.0

24.2–27.7

CRP

0.05

<0.01

  ≤ 10 (mg/L)

14.7

2.5–26.9

26.0

0.6–51.4

  > 10 (mg/L)

5.3

0.9–9.8

12.1

8.8–15.5

EORTC QoL symptom scale at BL

<0.01

0.01

 Upper quartile

2.8

2.2–3.5

12.7

4.8–20.7

 Lower 3 quartiles

14.7

4.6–24.8

25.2

12.7–37.7